Opendata, web and dolomites


Towards the prevention of aminoglycoside antibiotic-related deafness

Total Cost €


EC-Contrib. €






 DesignerAntibiotics project word cloud

Explore the words cloud of the DesignerAntibiotics project. It provides you a very rough idea of what is the project "DesignerAntibiotics" about.

genetics    antimicrobials    inner    chemically    annual    maintaining    masters    effect    compounds    candidate    gt    22    london    distinction    ototoxicity    20    die    economically    patients    drawback    children    care    suffer    models    acquisition    urgent    murine    aminoglycosides    author    impedes    university    patented    deaf    safer    rare    amounts    annually    bacteria    irreversible    incurred    vitro    crystallography    guided    diminish    shown    generation    critically    group    1555a    class    investigation    biobank    cells    imperial    billion    publication    ear    potency    aminoglycoside    25    profoundly    treatment    resistant    damage    modify    first    human    structural    profound    100    neonatal    biology    published    journal    infections    stanford    resistance    exposed    caused    occurs    mitochondrial    despite    mutation    molecular    language    data    78    antibiotics    clinical    ucl    15    intensive    impairment    infancy    drug    dna    antibacterial    hearing    patient    incidence    phd    threatening    college    limits    million    life   

Project "DesignerAntibiotics" data sheet

The following table provides information about the project.


Organization address
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 251˙857 €
 EC max contribution 251˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-02-13   to  2020-02-12


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 251˙857.00


 Project objective

Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf.

Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DESIGNERANTIBIOTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DESIGNERANTIBIOTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

HarmonizATforms (2019)

Defining the antithrombin measurand: role of proteoforms in harmonisation of diagnostic tests in thrombosis

Read More  

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  


Investigation of the SNP-induced RNA structure variations between subgenomes in polyploid wheat

Read More